Phase III data demonstrated clinically meaningful 35.1% proteinuria reduction 6; also, a stabilization of estimated glomerular filtration rate (eGFR) – a key measure of kidney function – was observed ...
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to ...
7th Floor, Bandra-Kurla Complex, ...
"The only way we can take care of our families is if we're around to do it," says Rodney Gillespie, US Head of Oncology at Novartis. For Rodney, cancer care isn’t just a professional responsibility—it ...
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway Abelacimab is currently in ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH) 1,2 Significant unmet need remains in PNH, a chronic, rare and ...
诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件 ...
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback